Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African community.

Schmidt BM, Geldenhuys H, Tameris M, Luabeya A, Mulenga H, Bunyasi E, Scriba T, Hatherill M.

S Afr Med J. 2017 Nov 27;107(12):1078-1081. doi: 10.7196/SAMJ.2017.v107i12.12502.


Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.

Schmidt BM, Tameris M, Geldenhuys H, Luabeya A, Bunyasi E, Hawkridge T, McClain JB, Mahomed H, Scriba TJ, McShane H, Hatherill M.

Trop Med Int Health. 2018 Jan;23(1):63-68. doi: 10.1111/tmi.13009. Epub 2017 Dec 4.


Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.

Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM, Hanekom WA, Mahomed H, McShane H, Hatherill M.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):778-783. doi: 10.5588/ijtld.16.0709.


Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol.

Bunyasi EW, Schmidt BM, Abdullahi LH, Mulenga H, Tameris M, Luabeya A, Shenje J, Scriba T, Geldenhuys H, Wood R, Hatherill M.

BMJ Open. 2017 Mar 10;7(3):e014609. doi: 10.1136/bmjopen-2016-014609. Review.


Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.

Bunyasi EW, Tameris M, Geldenhuys H, Schmidt BM, Luabeya AK, Mulenga H, Scriba TJ, Hanekom WA, Mahomed H, McShane H, Hatherill M.

PLoS One. 2015 Nov 10;10(11):e0141623. doi: 10.1371/journal.pone.0141623. eCollection 2015.


First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, Andersen P, Scriba TJ; H56-032 Trial Study Group, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, Hughes EJ, Bang P, Snowden MA, McClain B, Hussey GD.

Vaccine. 2015 Aug 7;33(33):4130-40. doi: 10.1016/j.vaccine.2015.06.051. Epub 2015 Jun 19.


A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.


Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients.

Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, Cangelosi GA.

Sci Rep. 2015 Mar 2;5:8668. doi: 10.1038/srep08668.


The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.

PLoS One. 2014 Feb 3;9(2):e87340. doi: 10.1371/journal.pone.0087340. eCollection 2014.


Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.

Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H.

Tuberculosis (Edinb). 2013 Mar;93(2):143-9. doi: 10.1016/ Epub 2013 Feb 12.


Analysis of time to regulatory and ethical approval of SATVI TB vaccine trials in South Africa.

Geldenhuys H, Veldsman A, Tameris M, Luabeya A, Hanekom W, Mahomed H, Hatherill M.

S Afr Med J. 2012 Nov 8;103(2):85-9. doi: 10.7196/samj.6390.


Supplemental Content

Loading ...
Support Center